Impact of the NRF2 activator, stabilised synthetic sulforaphane, on systemic inflammation in COVID19: results from the STAR-COVID19 trial

M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)

Source: International Congress 2022 – COVID basic science

Session: COVID basic science
Session type: Thematic Poster
Number: 4066

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom). Impact of the NRF2 activator, stabilised synthetic sulforaphane, on systemic inflammation in COVID19: results from the STAR-COVID19 trial. 4066

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.